Fig 2: Inhibition of miR-92a suppresses viability of non-small-cell lung cancer cells. (A) miR-92a expression was measured by reverse transcription-quantitative PCR after miR-92a inhibitor transfection. (B) miR-92a inhibitor was transfected into A549 and H1299 cells. The effects of miR-92a on A549 and H1299 cell viability were examined using an MTT assay at 24, 36 and 48 h post-transfection. (C) Protein expression levels of PCNA and Ki-67 in A549 and H1299 cells were measured by western blot analysis. Relative protein expression levels of PCNA and Ki-67 were normalized to the protein expression levels of ß-actin. Data are presented as mean of three replicates ± SD. Unpaired t-test; *P<0.05 and **P<0.01 vs. inhibitor NC group. NC, negative control; miR, microRNA; PCNA, proliferating cell nuclear antigen.

Fig 3: Decreased proliferation in retinas from conditional Bim mice.Proliferating cells in P14 wild-type, BimEC and BimPC mouse retinas were assessed by anti-Ki-67 staining (red) and co-stained with Isolectin-B4-FITC (green) to visualize the vasculature. The data in each bar are the mean number of Ki-67 positive cells counted in each retina. Please note that the number of proliferating cells is lower in retinas from conditional Bim mice compared to their wild-type counterparts (n = 6, ****P< 0.0001). Scale bar equals 400 µm.

Fig 4: Overexpression of circSNRK reduces cardiomyocyte apoptosis and promotes adult cardiac regeneration after MI.A TUNEL immunofluorescence staining in the AAV9 ctrl and AAV9 circSNRK groups 7 days post MI and quantification of TUNEL positive CMs. ***p < 0.001 vs. Sham + AAV9 ctrl, ###p < 0.001 vs. MI + AAV9 ctrl; bar = 25 µm. (n = 5–6 for each group). B BCL-2, BAX, cleaved-caspase-3/caspase-3 levels in heart tissue after AAV9 ctrl and AAV9 circSNRK treatment. ***p < 0.001 vs. Sham + AAV9 ctrl, ###p < 0.001 vs. MI + AAV9 ctrl (n = 3). C Ki67 immunofluorescence staining in adult rat hearts 14 days after transfection with AAV9 circSNRK and AAV9 ctrl and quantification of Ki67-positive cardiomyocytes. ***p < 0.001 vs. Sham + AAV9 ctrl group; ###p < 0.001 vs. MI + AAV9 ctrl group. bar = 25 µm (n = 5–6 for each group). D a-SMA (a-smooth muscle actin) staining in the AAV9 ctrl and AAV9 circSNRK groups 14 days after transfection with AAV9 circSNRK and AAV9 ctrl and quantification of a-SMA-positive capillaries, ***p < 0.001 vs. Sham + AAV9 ctrl group; ###p < 0.001 vs. MI + AAV9 ctrl group. bar = 25 µm (n = 5–6 for each group). E CD31 staining in the border zone of ischemic hearts and quantification of CD31 positive blood vessels. **p < 0.01 vs. Sham + AAV9 ctrl group; ###p < 0.001 vs. MI + AAV9 ctrl group. bar = 25 µm (n = 5–6 for each group).

Fig 5: Downregulation of RPLP1 inhibits the proliferation of Hep3b cells. (A) Reverse transcription-quantitative PCR analysis was performed to detect RPLP1 mRNA expression in Hep3b cells. (B) A Cell Counting Kit-8 assay was performed to assess cell viability. (C) A colony formation assay was performed to assess cell proliferation. (D) Immunofluorescence analysis was performed to detect Ki-67 expression. Scale bars, 50 µm. (E) Western blot analysis was performed to detect the protein expression levels of MCM and PCNA. **P<0.01, ***P<0.001 vs. control. RPLP1, ribosomal protein LP1; MCM, minichromosome maintenance; PCNA, proliferating cell nuclear antigen; sh, short hairpin; NC, negative control.